Could the Difference Between Normal and Malignant Stem Cells Eradicate Cancer?

Ivanovic, Zoran
October 2013
Scripta Medica;Oct2013, Vol. 44 Issue 2, p74
Academic Journal
The authors discuss the role of normal stem cells in the eradication of cancer. They consider cellular therapy as a real medical revolution prompted by stem cell research in the 21st century. They describe the commonality between normal and cancer stem cells based on the findings of stem cell research.


Related Articles

  • Blazing a new TRAIL in hematopoietic cell transplantation. Chao, Nelson // Journal of Clinical Investigation;Jul2013, Vol. 123 Issue 7, p2362 

    There is a ying/yang to most biological therapies, and the balance of efficacy versus toxicity is delicate and sometimes difficult to achieve in favor of the patients. When the therapeutic window is wide, these therapies can be used in the majority of patients, but when the therapeutic window is...

  • Life in Limbo: Experiences of Iranian Hematopoietic Stem Cell Transplantation Recipient Patients and Nurses in a Qualitative Study. Zamanzadeh, Vahid; Valizadeh, Leila; Sayadi, Leila; Taleghani, Fariba; Jeddian, Alireza // International Journal of Hematology-Oncology & Stem Cell Researc;Jul2013, Vol. 7 Issue 3, p24 

    Background: This study explored the state of hematopoietic stem cell transplantation (HSCT) recipient patients and problems experienced by them and nurse about these state and problems, in Iran. Methods: Qualitative content analysis was used for analyzing semi-structured interviews with 12 HSCT...

  • The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma. Pham, R. N.; Gooley, T. A.; Keeney, G. E.; Press, O. W.; Pagel, J. M.; Greisman, H. A.; Bensinger, W. I.; Holmberg, L. A.; Petersdorf, S. H.; Maloney, D. G.; Gopal, A. K. // Bone Marrow Transplantation;Dec2007, Vol. 40 Issue 11, p1039 

    The impact of the follicular lymphoma (FL) histologic grade on outcomes after high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) is unknown. We evaluated 219 consecutive patients with grades 1–3 FL who underwent HDT and ASCT at our center. Overall survival (OS),...

  • Cognate antigen directs CD8+ T cell migration to vascularized transplants. Walch, Jeffrey M.; Qiang Zeng; Qi Li; Oberbarnscheidt, Martin H.; Hoffman, Rosemary A.; Williams, Amanda L.; Rothstein, David M.; Shlomchik, Warren D.; Kim, Jiyun V.; Camirand, Geoffrey; Lakkis, Fadi G. // Journal of Clinical Investigation;Jul2013, Vol. 123 Issue 7, p2663 

    The migration of effector or memory T cells to the graft is a critical event in the rejection of transplanted organs. The prevailing view is that the key steps involved in T cell migration -- integrin-mediated firm adhesion followed by transendothelial migration -- are dependent on the...

  • Tracking the engraftment and regenerative capabilities of transplanted lung stem cells using fluorescent nanodiamonds. Wu, Tsai-Jung; Tzeng, Yan-Kai; Chang, Wei-Wei; Cheng, Chi-An; Kuo, Yung; Chien, Chin-Hsiang; Chang, Huan-Cheng; Yu, John // Nature Nanotechnology;Sep2013, Vol. 8 Issue 9, p682 

    Lung stem/progenitor cells are potentially useful for regenerative therapy, for example in repairing damaged or lost lung tissue in patients. Several optical imaging methods and probes have been used to track how stem cells incorporate and regenerate themselves in vivo over time. However, these...

  • Pilot study of patient and caregiver out-of-pocket costs of allogeneic hematopoietic cell transplantation. Majhail, N S; Rizzo, J D; Hahn, T; Lee, S J; McCarthy, P L; Ammi, M; Denzen, E; Drexler, R; Flesch, S; James, H; Omondi, N; Pedersen, T L; Murphy, E; Pederson, K // Bone Marrow Transplantation;Jun2013, Vol. 48 Issue 6, p865 

    Patient/caregiver out-of pocket costs associated with hematopoietic cell transplantation (HCT) are not well known. We conducted a pilot study to evaluate patient/caregiver out-of-pocket costs in the first 3 months after allogeneic HCT. Thirty patients were enrolled at three sites. Before HCT,...

  • Inhibition of PTEN Tumor Suppressor Promotes the Generation of Induced Pluripotent Stem Cells. Liao, Jiyuan; Marumoto, Tomotoshi; Yamaguchi, Saori; Okano, Shinji; Takeda, Naoki; Sakamoto, Chika; Kawano, Hirotaka; Nii, Takenobu; Miyamato, Shohei; Nagai, Yoko; Okada, Michiyo; Inoue, Hiroyuki; Kawahara, Kohichi; Suzuki, Akira; Miura, Yoshie; Tani, Kenzaburo // Molecular Therapy;Jun2013, Vol. 21 Issue 6, p1242 

    Induced pluripotent stem cells (iPSCs) can be generated from patients with specific diseases by the transduction of reprogramming factors and can be useful as a cell source for cell transplantation therapy for various diseases with impaired organs. However, the low efficiency of iPSC derived...

  • Chimerism and use of mesenchymal stem cells in umbilical cord blood transplantation. Berglund, Sofia; Uhlin, Michael; Mattsson, Jonas // Chimerism;Jan-Mar2013, Vol. 4 Issue 1, Special section p1 

    The article discusses a study which investigated chimerism and the use of mesenchymal stem cells in umbilical cord blood transplantation. The researchers conducted a retrospective single-center analysis of 50 umbilical cord blood transplantations (UCBTs). It was concluded that mixed chimerism...

  • Redefining strategies to introduce tolerance inducing cellular therapy in humans to combat autoimmunity and transplantation reactions. ten Brinke, Anja; Joosten, Irma; van Ham, S. Marieke; van Kooten, Cees; Prakken, Berent J. // Frontiers in Immunology;Jul2014, Vol. 5, p1 

    Clinical translation of tolerance-inducing cell therapies requires a novel approach focused on innovative networks, patient involvement and, foremost, a fundamental paradigm shift in thinking from both Academia, Industry and Regulatory Agencies. Tolerance-inducing cell products differ...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics